Shattuck Labs has pivoted from oncology to focus on immunology, specifically developing DR3-targeted therapies for inflammatory bowel disease (IBD). Their lead candidate, SL-325, demonstrated strong safety, low immunogenicity, and durable receptor occupancy in Phase 1 trials, supporting the possibility of quarterly dosing. The company is financially secure through Phase 2b with a cash runway into 2029 despite dilution. Future success depends on SL-325's clinical efficacy compared to existing anti-TL1A treatments, while another candidate, SL-846, could expand their platform if DR3 targeting proves effective.
Alphabet CEO Sundar Pichai revealed that the company is facing challenges in rapidly expanding its AI capacity to meet demand. Meanwhile, competitor Anthropic has successfully secured 5 gigawatts of AI computing power, highlighting a significant deve...
Youlife Group's subsidiary has signed a five-year strategic cooperation agreement with Ji'an Industry-Education Integration Technology to develop a vocational education park in Jiangxi, China. The park will focus on integrating vocational education w...
Syra Health has expanded its partnership with Wake County Public Health in North Carolina by launching Wellness S.P.A. 2.0, an employee wellness program aimed at supporting mental and emotional health, preventing burnout, and building resilience amon...
Broadcom's stock has fallen 25% from its peak, trading around $370 while Wall Street analysts average a $526 price target, with BNP Paribas Exane projecting an 82% upside to $675. The company benefits from strong AI semiconductor growth, with a $30 b...
Gold and silver prices fell significantly in early U.S. trading due to a global bond selloff, a stronger U.S. dollar, and rising oil prices, as markets priced in a higher chance of a Federal Reserve rate hike in September. Spot gold dropped to around...
